Sugi Predict

Sugi Predict / Compounds / Guanine

Guanine

Guanine

SCHEMBL629581

Nc1nc2nc[nH]c2c(=O)[nH]1.O=c1[nH]c(=O)c2[nH]cnc2[nH]1.O=c1[nH]cnc2nc[nH]c12

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 2/20 0.72
▸ GDA Q9Y2T3 2/20 0.64
▸ ACHE P22303 1/20 0.64
▸ ALDH1A1 P00352 3/20 0.50
▸ MAPT P10636 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ USP2 O75604 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ ADORA3 P0DMS8 1/20 0.44
▸ PTGS1 P23219 1/20 0.44
▸ MAPK3 P27361 1/20 0.44
▸ XDH P47989 1/20 0.44
▸ HBB P68871 1/20 0.44
▸ PAX8 Q06710 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanine SCHEMBL72148 0.97 PNP (0.77) PNPGDAACHEALDH1A1MAPT
Guanine SCHEMBL28135092 0.96 PNP (0.74) PNPGDAACHEALDH1A1MAPT
Guanine SCHEMBL28018185 0.91 PNP (0.67) PNPGDAACHEALDH1A1MAPT
Guanine SCHEMBL8090344 0.90 PNP (0.65) PNPGDAACHEALDH1A1MAPT
Guanine SCHEMBL3515114 0.89 GDA (0.56) PNPGDAACHEALDH1A1MAPT
Guanine SCHEMBL28068968 0.89 PNP (0.63) PNPGDAACHEALDH1A1MAPT
Guanine SCHEMBL38408 0.88 PNP (0.93) PNPGDAALDH1A1MAPTHPGD
Guanine SCHEMBL20797883 0.88 PNP (0.93) PNPGDAALDH1A1MAPTHPGD
Xanthine SCHEMBL160198 0.88 GDA (0.82) PNPGDAACHEALDH1A1XDH
Xanthine SCHEMBL4295220 0.87 GDA (0.79) PNPGDAACHEALDH1A1XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2847201-B1 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS UNIV QUEENSLAND (AU) 2017-08-16 — — EP claimed
WO-2017100849-A1 6-OXOPURINE PHOSPHORIBOSYL TRANSFERASE INHIBITORS THE UNIVERSITY OF QUEENSLAND (AU) 2017-06-22 — — WO claimed
EP-2847201-A2 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS The University of Queensland (AU) 2015-03-18 — — EP claimed
WO-2013166545-A2 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS THE UNIVERSITY OF QUEENSLAND (AU) 2013-11-14 — — WO claimed
EP-1487852-A4 ANTI-PROTOZOAL VACCINE QUEENSLAND INST MED RES (AU) 2006-02-22 — — EP claimed
US-20050123557-A1 AntiI-protozoal vaccine THE COUNCIL OF HTE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2005-06-09 — — US claimed
EP-1487852-A1 ANTI-PROTOZOAL VACCINE THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2004-12-22 — — EP claimed
WO-2003074543-A1 ANTI-PROTOZOAL VACCINE THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2003-09-12 — — WO claimed
US-20240238398-A1 IMMUNOGENIC COMPOSITION GRIFFITH UNIVERSITY (AU) 2024-07-18 — — US disclosed
EP-4337231-A1 IMMUNOGENIC COMPOSITION Griffith University (AU) 2024-03-20 — — EP disclosed
US-20200101091-A1 ACYLNUCLEOSIDE PHOSPHONATES, PRODRUGS THEREOF AND USE THEREOF AS MEDICAMENT ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER (FR) 2020-04-02 — — US disclosed
EP-3601302-A1 ACYLNUCLEOSIDE PHOSPHONATES, PRODRUGS THEREOF AND USE THEREOF AS MEDICAMENT Université de Montpellier (FR) 2020-02-05 — — EP disclosed
WO-2018172435-A1 ACYLNUCLEOSIDE PHOSPHONATES, PRODRUGS THEREOF AND USE THEREOF AS MEDICAMENT UNIVERSITE DE MONTPELLIER (FR) 2018-09-27 — — WO disclosed
CN-107075449-A Genetically modified coccidial parasites useful as vaccines 柏林洪堡大学 2017-08-18 — — CN disclosed
EP-1487852-A1 ANTI-PROTOZOAL VACCINE THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2004-12-22 — — EP disclosed
EP-1487852-A1 ANTI-PROTOZOAL VACCINE THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2004-12-22 — — EP disclosed
EP-1409681-A2 PROTEINS AND NUCLEIC ACIDS ENCODING SAME Curagen Corporation (US) 2004-04-21 — — EP disclosed
WO-2003074543-A1 ANTI-PROTOZOAL VACCINE THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2003-09-12 — — WO disclosed
WO-2003074543-A1 ANTI-PROTOZOAL VACCINE THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2003-09-12 — — WO disclosed
WO-2002068649-A2 PROTEINS AND NUCLEIC ACIDS ENCODING SAME CURAGEN CORPORATION (US) 2002-09-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200101091-A1 ACYLNUCLEOSIDE PHOSPHONATES, PRODRUGS THEREOF AND USE THEREOF AS MEDICAMENT PNP, TYMP, PPA1 PNP 1/4885GDA 100/4885ACHE 1325/4885
US-20240238398-A1 IMMUNOGENIC COMPOSITION CD47, CD74, CD14 PNP 2898/4885GDA 2074/4885ACHE 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.